Business Context and Reporting Period
Company: Bone Biologics Corp
Filing Type: Form 8-K (Current Report)
Date of Report: October 2, 2015
Event Date: September 24, 2015 (Agreement signed), effective October 2, 2015
The Company entered into a Letter Agreement with its Founders (Dr. Chia Soo, Dr. Eric Kang Ting, and Dr. Ben Wu) regarding the transfer of intellectual property and data related to the Company's core asset, Nell-1.
Key Financial Metrics
This filing is a current report regarding a material definitive agreement and unregistered sales of equity. It does not contain periodic financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Transaction Details
- Asset Transfer: The Founders agreed to deliver all past work product and data related to Nell-1 to the Company for its sole discretion, subject to University of California licensing rights.
- Equity Consideration: In exchange, the Company agreed to issue an aggregate of 1,153,846 shares of common stock (par value $0.001) to the Founders.
- Issuance Timing: Shares are to be equally distributed among the Founders upon the earlier of:
- The third anniversary of the Agreement.
- The occurrence of a "Liquidity Event" as defined in the agreement.
- Registration Rights: The Shares include piggyback registration rights upon the occurrence of an equity financing by the Company.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard incorporation of the full Letter Agreement text. The primary contingency noted is the timing of the share issuance, which is dependent on a future Liquidity Event or the passage of three years.
Key Facts for Investor Verification
- Verify the definition of "Liquidity Event" in the full text of the Letter Agreement (Exhibit 10.1) to understand the potential acceleration of share issuance.
- Confirm the current licensing status and scope of rights granted by the University of California regarding Nell-1 data.
- Assess the dilution impact of the 1,153,846 shares relative to the Company's current outstanding share count.
- Review the Company's capitalization table to determine the percentage ownership the Founders will hold post-issuance.